Patiromer and Scopolamine

• Generic Name: patiromer
• Dosage Forms: n.a.
• Other Brand Names: Veltassa

Patiromer is a medicine that binds itself to potassium in your digestive tract. This helps prevent your body from absorbing too much potassium. Patiromer also helps your body get rid of excess potassium through your stools (bowel movements).

Patiromer is used to treat hyperkalemia (high levels of potassium in your blood).

Patiromer works differently from other medicines because it passes through your stomach and into your intestines without being absorbed into your blood stream.

Patiromer may also be used for purposes not listed in this medication guide.

• Generic Name: scopolamine
• Dosage Forms: n.a.
• Other Brand Names: Transderm-Scop

Prevention of motion-induced nausea and vomiting; considered most effective drug for this use.

Oral or IM administration usually reserved for patients exposed to short periods of intense motion or those highly susceptible to motion because these routes have short duration of effect and high incidence of adverse effects.

Transdermal administration is effective and has fewer adverse effects and increased duration compared with oral administration.

Used transdermally for prevention of nausea and vomiting associated with recovery from anesthesia and surgery, but efficacy is equivocal.

Has been used preoperatively to inhibit salivation and excessive respiratory tract secretions, but use of general anesthetics (e.g., thiopental [no longer commercially available in the US], halothane) that do not stimulate secretions has reduced the need for this use.

Used preoperatively and in obstetrics in conjunction with analgesics or sedatives to produce tranquilization and amnesia; however, benzodiazepines may be preferred.

Has greater sedative, antisecretory (e.g., on respiratory secretions), and antiemetic effects than atropine; however, less effective than atropine in preventing intraoperative cholinergic effects (e.g., cardiac arrhythmias, hypotension, bradycardia).

Has been used for symptomatic treatment of parkinsonian syndrome; however, antimuscarinincs generally have been replaced with dopaminergic drugs.